Group 1 - The visit of South Korean President Lee Jae-myung to China from January 4 to 7 marks a significant diplomatic event, being his first state visit to China and the first foreign leader to visit China in 2026, symbolizing a warming of relations between the two countries [2][3] - The meeting is expected to strengthen bilateral communication channels, focusing on economic cooperation and restoring bilateral relations, which is seen as a major diplomatic achievement for the current South Korean government [3][4] - The historical context of the visit highlights the deep-rooted ties between China and South Korea, with both countries having supported each other during significant historical events, such as the anti-fascist war [5] Group 2 - A large economic delegation from South Korea, including leaders from major conglomerates, accompanied President Lee, indicating a strong interest in exploring collaboration in manufacturing, supply chains, and service industries [6][7] - The bilateral trade volume between China and South Korea reached $328.08 billion in 2024, with trade increasing over 60 times since the establishment of diplomatic relations in 1992, showcasing the economic interdependence between the two nations [6] - The rise of a trend in South Korea to "learn from China" in advanced industries like artificial intelligence and robotics reflects a growing recognition of China's leadership in these sectors [6][7] Group 3 - Cultural exchanges are increasingly important, with South Korean cosmetics gaining popularity in China and Chinese smart appliances thriving in the South Korean market, indicating a growing mutual appreciation and economic interaction [9][10] - The implementation of visa facilitation measures in 2024 and 2025 has led to a significant increase in people-to-people exchanges, with over 1,000 regular flights per week between the two countries [10] - The historical connections between the two nations, including shared experiences during the anti-Japanese war, serve as a foundation for deepening mutual understanding and emotional ties [11]

Group 1 - A patient, Ms. Liu, experienced severe complications after undergoing eyelid fat removal surgery at Jingxi Medical Aesthetics in Nanjing, including blurred vision, photophobia, tearing, and eye pain [1][2] - The local health authorities, including Jiangsu Provincial Health Commission and Nanjing Municipal Health Commission, have intervened following media coverage of the incident, indicating a high level of concern regarding the medical dispute [1][2] - Jingxi Medical Aesthetics has refused to mediate the dispute, insisting that Ms. Liu pursue legal channels for compensation if medical assessments confirm that the surgery caused her symptoms [2] Group 2 - The health authorities have conducted investigations into Ms. Liu's complaints but have found no evidence of illegal activity by the medical institution at this time [1] - The medical institution claims that Ms. Liu frequently visits to assert her rights, and the media coverage has significantly impacted their reputation [2] - The health authorities plan to conduct focused inspections of the medical aesthetics institution and will enforce strict penalties if any violations are discovered [2]

Group 1 - The establishment of Beijing Ningyue Medical Aesthetic Clinic Co., Ltd. has been officially registered, with a registered capital of 1 million RMB and a broad range of services including medical and lifestyle beauty services [1] - The company is primarily owned by Beijing Dingdong Lemon Technology Co., Ltd., which holds 90% of the shares, while Jin Peng holds the remaining 10%. Notably, Gan Wei owns 13.965% of Beijing Dingdong Lemon Technology Co., Ltd. [1] - Wang Sicong and Qin Lan hold indirect stakes in Beijing Dingdong Lemon Technology Co., Ltd. through Beijing Ningyue Technology Center (Limited Partnership) [1] Group 2 - This is not Wang Sicong's first venture into the medical beauty sector, as he was a co-founder of the Ningyue brand during its launch event in December 2016 [4] - Prior reports indicated that Ningyue Clinic's membership cards had reached 70% coverage among celebrities and influencers, which could enhance brand reputation and attract both fans and general consumers [4] - Currently, there is only one operational store for Ningyue Medical Aesthetics in Beijing, with an average consumer spending of 2,409 RMB. Another store is under renovation, with no confirmed opening date yet [4]

由于此前医美企业并未被排除在免税医疗机构范围之外，因此只要符合财政部、税务总局发布的相关医 疗服务免税政策条件，如这一服务属于《全国医疗服务价格项目规范》所列的各项服务，且价格不高于 官方医疗服务指导价格等，在部分地方可以享受免税政策。 中南财经政法大学税收治理研究中心主任田彬彬告诉第一财经，此前部分医疗美容业务可以享受免征增 值税的优惠，主要是因为这些业务通常被归类为医疗服务的一部分，而医疗服务在增值税法中一般是免 税的。同时，免税政策也出于对医美行业扶持和发展的考虑，尤其是在医美行业发展的初期，通过减轻 税负促进行业增长。 田彬彬表示，但这也导致医美行业一直利用"医疗机构"这一身份，在"医疗治病"与"商业美容"的模糊地 带享受免税优惠。并且，随着该行业的快速发展和市场化程度的提高，越来越多的医美项目走向盈利 化、商业化。因此有必要取消营利性美容医疗机构免征增值税优惠政策。 他解释，增值税免税是一种"福利"。国家希望通过免税降低老百姓看病救命的成本。而美容医疗更多属 于消费升级和悦己消费，不具备"基本医疗保障"的属性，应当取消免税优惠。另外传统的生活美容服务 一直是缴纳增值税，而医美机构因挂了"医疗"牌子就 ...

证券之星消息，1月6日医疗美容板块较上一交易日上涨0.66%，爱美客领涨。当日上证指数报收于 4083.67，上涨1.5%。深证成指报收于14022.55，上涨1.4%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 146.49 | 1.06% | 3.41万 | 4.98 乙 | | 688363 | 华熙生物 | 44.91 | 0.34% | 5.16万 | 2.31亿 | | 920982 | 锦波生物 | 236.12 | -0.22% | 7324.94 | 1.74亿 | | 000615 | *ST美谷 | 3.46 | -0.86% | 13.90万 | 4782.12万 | 从资金流向上来看，当日医疗美容板块主力资金净流出1283.62万元，游资资金净流入772.62万元，散户 资金净流入511.0万元。医疗美容板块个股资金流向见下表： | 代码 | 名称 | 主力净流入 (元) | | | 主力净占比 游资净流入 ...

Core Viewpoint - Furuya Medical Technology (01696) has successfully passed the quality standard inspection for its long-acting botulinum toxin product DAXXIFY, marking a significant milestone for its market entry in China [1] Group 1: Product Development - DAXXIFY has met the stringent quality, safety, and efficacy requirements set by the National Medical Products Administration of China, completing the final critical step before market launch [1] - The product is expected to enhance the diversity of the company's injectable filler offerings, providing consumers with more high-quality choices [1] Group 2: Business Impact - DAXXIFY is positioned as a strategic cornerstone for the company's injectable filler business, anticipated to serve as a second growth engine and generate sustainable consumable revenue [1] - The successful launch of DAXXIFY is expected to strengthen the company's leading position in the global beauty and health industry [1]

证券之星消息，1月5日医疗美容板块较上一交易日上涨2.22%，华熙生物领涨。当日上证指数报收于 4023.42，上涨1.38%。深证成指报收于13828.63，上涨2.24%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688363 | 华熙生物 | 44.76 | 2.47% | 4.79万 | 2.14亿 | | 300896 | 爱美客 | 144.95 | 2.28% | 3.97万 | 5.72亿 | | 920982 | 锦波生物 | 236.64 | 1.26% | 7690.59 | 1.80 Z | | 000615 | *ST美谷 | 3.49 | 0.00% | 11.32万 | 3982.21万 | 从资金流向上来看，当日医疗美容板块主力资金净流入1362.9万元，游资资金净流出704.42万元，散户资 金净流出658.47万元。医疗美容板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345 ...

Group 1 - CITIC Securities maintains a "Buy" rating for Huahong Semiconductor (01347.HK) with a target price of HKD 100, highlighting its leading position in specialty process wafer foundry and strong growth potential from capacity expansion and acquisitions [1] - CITIC Securities also maintains a "Buy" rating for SiHuan Pharmaceutical (00460.HK) with a target price of HKD 1.6, noting rapid growth in its medical aesthetic products and strong sales performance of new regenerative products [1] - GF Securities maintains a "Buy" rating for Yum China (09987.HK) with a target price of HKD 453.62, citing improved same-store sales and growth driven by new product iterations and marketing strategies [1] Group 2 - GF Securities initiates coverage on Laoputang Gold (06181.HK) with a "Buy" rating and a target price of HKD 775.64, emphasizing its leading position in handcrafted gold jewelry and strong growth potential from store expansion [2] - GF Securities initiates coverage on Yue Yuen Industrial (00551.HK) with a "Buy" rating and a target price of HKD 19.99, highlighting its status as the largest athletic shoe manufacturer and expected performance recovery [3] Group 3 - Cinda International maintains a "Buy" rating for Hesai Technology (02525.HK), noting its leadership in the global LiDAR market and significant growth in production and market share [4] - Zhongtai Securities initiates coverage on China Resources Land (01109.HK) with an "Accumulate" rating, reporting strong revenue and profit growth along with a healthy financial structure [5] Group 4 - First Shanghai initiates coverage on Jaxin International Resources (03858.HK) with a "Buy" rating and a target price of HKD 82.4, highlighting its world-class tungsten resources and strong profit growth potential [6] - Kaiyuan Securities initiates coverage on Beautiful Pastoral Medical Health (02373.HK) with a "Buy" rating, emphasizing its differentiated business model and effective customer acquisition strategies [7] Group 5 - CICC maintains an "Outperform" rating for Standard Chartered Group (02888.HK), noting better-than-expected Q2 2025 performance driven by significant growth in non-interest income [8]

Group 1: Market Overview - The A-share market in 2025 experienced extreme polarization, with some stocks soaring while others plummeted, indicating a significant shift in investor sentiment towards new productivity sectors [1][9] - Over 4,000 stocks rose, with the ChiNext index increasing nearly 50%, yet 40 stocks saw declines exceeding 30%, reflecting a collective flight from traditional industries [1] Group 2: Real Estate Sector - Vanke A and Poly Developments, once leading real estate companies, faced declines of 34.71% and 28.77% respectively due to tightening real estate policies and low consumer confidence [3] - The sales revenue for these companies dropped sharply, as market funds shifted away from real estate towards technology and new energy sectors [3] Group 3: Automotive Industry - SAIC Motor Corporation experienced a decline of 25.64%, struggling to adapt to the rapid transition to new energy vehicles amid competition from BYD and Tesla [3] - The company's sales growth in the new energy vehicle segment fell short of expectations, while the traditional fuel vehicle market continued to shrink [3] Group 4: Alcohol Industry - The white liquor sector saw significant divergence, with Yanghe and Wuliangye declining by 22.07% and 19.96% respectively, while Moutai and Luzhou Laojiao remained stable [3] - Weak consumer recovery and high channel inventory pressured prices, particularly for Yanghe, which lacked innovation and marketing appeal [3] Group 5: Medical Aesthetics Sector - Aimeike, a leader in the medical aesthetics industry, fell by 20.56% due to stricter regulations and intensified market competition, leading to a decline in core product growth [5] - The industry faced challenges from consumption downgrades and product homogenization, undermining previous high-growth narratives [5] Group 6: ST Stocks and Market Dynamics - 2025 was marked as the "year of new delisting regulations," with ST stocks suffering severe declines, such as Zitian's drop of over 96% due to financial fraud [5][9] - The phenomenon of increasing shareholder numbers in declining ST stocks highlighted a dangerous "buy the dip" mentality among investors [7] Group 7: Technology Sector - Companies like Aowei New Materials and Tianpu Holdings saw extraordinary gains of 1820% and 1662% respectively, driven by trends in humanoid robotics and AI chips [1][7] - Shenghong Technology emerged as a significant player in the AI sector, with a net profit surge of 324% and a market capitalization exceeding 260 billion yuan [7] Group 8: Overall Market Metrics - The total market capitalization of A-shares surpassed 109 trillion yuan, with a trading volume of 419.86 trillion yuan and a margin balance of 2.55 trillion yuan [9] - Extreme cases of liquidity issues were noted, such as ST Suwu's minimum daily trading volume of only 70,000 yuan, indicating potential risks in market liquidity [9]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 誠如2025年中期報告「所得款項用途」一節所披露，所得款項淨額擬用作以下用途： 上市所得款項淨額為約81.7百萬港元（經扣除包銷佣金及相關成本及開支後）。 1 Raily Aesthetic Medicine International Holdings Limited 瑞麗醫美國際控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2135） 更改所得款項淨額用途 茲提述(i) 瑞麗醫美國際控股有限公司（「本公司」）日期為2020年12月15日有關本 公司股份於香港聯合交易所有限公司上市（「上市」）的招股章程（「招股章程」）， 當中詳述（其中包括）於刊發招股章程時發行本公司新股份所得款項淨額（「所得 款項淨額」）的擬定用途；(ii)本公司日期為2025年3月28日之截至2024年12月31日止 年度之年度報告（「2024年年報」）；(iii) 日期為2025年10月10日之有關2024年年報 ...